CL2023002383A1 - Compuesto de quinazolina para inducir la degradación de la proteína kras mutante g12d - Google Patents
Compuesto de quinazolina para inducir la degradación de la proteína kras mutante g12dInfo
- Publication number
- CL2023002383A1 CL2023002383A1 CL2023002383A CL2023002383A CL2023002383A1 CL 2023002383 A1 CL2023002383 A1 CL 2023002383A1 CL 2023002383 A CL2023002383 A CL 2023002383A CL 2023002383 A CL2023002383 A CL 2023002383A CL 2023002383 A1 CL2023002383 A1 CL 2023002383A1
- Authority
- CL
- Chile
- Prior art keywords
- pancreatic cancer
- quinazoline compound
- compound
- kras protein
- mutant kras
- Prior art date
Links
- -1 Quinazoline compound Chemical class 0.000 title abstract 3
- 230000015556 catabolic process Effects 0.000 title abstract 2
- 238000006731 degradation reaction Methods 0.000 title abstract 2
- 101150105104 Kras gene Proteins 0.000 title 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 4
- 201000002528 pancreatic cancer Diseases 0.000 abstract 4
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 4
- 102100030708 GTPase KRas Human genes 0.000 abstract 2
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 102200006539 rs121913529 Human genes 0.000 abstract 2
- 229940124597 therapeutic agent Drugs 0.000 abstract 2
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Proporcionar un compuesto útil como ingrediente activo de una composición farmacéutica para tratar el cáncer de páncreas. Los presentes inventores han estudiado un compuesto que es útil como ingrediente activo de una composición farmacéutica para tratar el cáncer de páncreas y han descubierto que un compuesto de quinazolina tiene una excelente acción inductora de degradación sobre una proteína KRAS mutante G12D y una actividad inhibidora de KRAS mutante G12D, y puede usarse como agente terapéutico para el cáncer de páncreas, con lo cual se completa la presente invención. El compuesto de quinazolina o una sal de este de la presente invención se puede usar como agente terapéutico para el cáncer de páncreas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021021656 | 2021-02-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023002383A1 true CL2023002383A1 (es) | 2024-01-19 |
Family
ID=82838828
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023002383A CL2023002383A1 (es) | 2021-02-15 | 2023-08-11 | Compuesto de quinazolina para inducir la degradación de la proteína kras mutante g12d |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20240182483A1 (es) |
| EP (1) | EP4293024A1 (es) |
| JP (2) | JP7169729B1 (es) |
| KR (1) | KR20230145361A (es) |
| CN (1) | CN116848120A (es) |
| AR (1) | AR124870A1 (es) |
| AU (1) | AU2022221145A1 (es) |
| BR (1) | BR112023015067A2 (es) |
| CA (1) | CA3211051A1 (es) |
| CL (1) | CL2023002383A1 (es) |
| CO (1) | CO2023010710A2 (es) |
| CR (1) | CR20230404A (es) |
| DO (1) | DOP2023000161A (es) |
| EC (1) | ECSP23067156A (es) |
| IL (1) | IL305077A (es) |
| MX (1) | MX2023009521A (es) |
| PE (1) | PE20240235A1 (es) |
| TW (1) | TW202245751A (es) |
| WO (1) | WO2022173032A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023119677A1 (en) * | 2021-12-24 | 2023-06-29 | Astellas Pharma Inc. | Pharmaceutical composition comprising a quinazoline compound |
| TW202346270A (zh) * | 2022-03-11 | 2023-12-01 | 日商安斯泰來製藥股份有限公司 | 用於誘發g12d突變kras蛋白分解之雜環化合物 |
| WO2024029613A1 (ja) * | 2022-08-05 | 2024-02-08 | アステラス製薬株式会社 | 変異ｋｒａｓタンパクの分解を誘導するための複素環化合物 |
| WO2024034593A1 (ja) * | 2022-08-09 | 2024-02-15 | アステラス製薬株式会社 | Ｇ１２ｖ変異ｋｒａｓタンパクの分解を誘導するための複素環化合物 |
| WO2024034591A1 (ja) * | 2022-08-09 | 2024-02-15 | アステラス製薬株式会社 | Ｋｒａｓタンパクを阻害及び／又は分解誘導するための複素環化合物 |
| WO2024033537A1 (en) * | 2022-08-12 | 2024-02-15 | Astellas Pharma Inc. | Combination of anticancer agents comprising a bifunctional compound with g12d mutant kras inhibitory activity |
| WO2024034123A1 (ja) * | 2022-08-12 | 2024-02-15 | アステラス製薬株式会社 | 複素環化合物を含む医薬組成物 |
| WO2024033538A1 (en) * | 2022-08-12 | 2024-02-15 | Astellas Pharma Inc. | Combination of anticancer agents comprising a bifunctional compound with g12d mutant kras inhibitory activity |
| CN115873018B (zh) * | 2022-11-18 | 2024-03-15 | 中国药科大学 | 苯并嘧啶和苯并三嗪类造血祖细胞激酶1降解剂及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102668696B1 (ko) | 2012-01-12 | 2024-05-29 | 예일 유니버시티 | E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법 |
| US20150291562A1 (en) | 2014-04-14 | 2015-10-15 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| WO2016049565A1 (en) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Compositions and methods for inhibition of ras |
| WO2016049568A1 (en) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Methods and compositions for inhibition of ras |
| US10822312B2 (en) | 2016-03-30 | 2020-11-03 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| JOP20190186A1 (ar) * | 2017-02-02 | 2019-08-01 | Astellas Pharma Inc | مركب كينازولين |
| MX2020010420A (es) | 2018-04-04 | 2020-12-11 | Arvinas Operations Inc | Moduladores de la proteólisis y métodos asociados de uso. |
| EP3823613A4 (en) | 2018-07-20 | 2022-05-11 | Dana Farber Cancer Institute, Inc. | DEGRADATION AGENTS TARGETING PROTEINS THROUGH KEAP1 |
| MX2022002465A (es) | 2019-08-29 | 2022-05-19 | Mirati Therapeutics Inc | Inhibidores de kras g12d. |
| TW202124374A (zh) | 2019-09-13 | 2021-07-01 | 美商拜歐斯瑞克斯公司 | Ras蛋白降解劑、其醫藥組合物及其治療應用 |
| WO2021106231A1 (en) | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
-
2022
- 2022-02-14 CR CR20230404A patent/CR20230404A/es unknown
- 2022-02-14 AU AU2022221145A patent/AU2022221145A1/en active Pending
- 2022-02-14 IL IL305077A patent/IL305077A/en unknown
- 2022-02-14 EP EP22752854.4A patent/EP4293024A1/en active Pending
- 2022-02-14 BR BR112023015067A patent/BR112023015067A2/pt unknown
- 2022-02-14 KR KR1020237027669A patent/KR20230145361A/ko unknown
- 2022-02-14 TW TW111105240A patent/TW202245751A/zh unknown
- 2022-02-14 US US18/268,001 patent/US20240182483A1/en active Pending
- 2022-02-14 MX MX2023009521A patent/MX2023009521A/es unknown
- 2022-02-14 CN CN202280014815.8A patent/CN116848120A/zh active Pending
- 2022-02-14 WO PCT/JP2022/005582 patent/WO2022173032A1/ja active Application Filing
- 2022-02-14 PE PE2023002366A patent/PE20240235A1/es unknown
- 2022-02-14 AR ARP220100290A patent/AR124870A1/es unknown
- 2022-02-14 CA CA3211051A patent/CA3211051A1/en active Pending
- 2022-02-14 JP JP2022542202A patent/JP7169729B1/ja active Active
- 2022-10-27 JP JP2022172197A patent/JP2022191505A/ja active Pending
-
2023
- 2023-08-11 CL CL2023002383A patent/CL2023002383A1/es unknown
- 2023-08-15 DO DO2023000161A patent/DOP2023000161A/es unknown
- 2023-08-16 CO CONC2023/0010710A patent/CO2023010710A2/es unknown
- 2023-09-05 EC ECSENADI202367156A patent/ECSP23067156A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP7169729B1 (ja) | 2022-11-11 |
| BR112023015067A2 (pt) | 2023-10-03 |
| CO2023010710A2 (es) | 2023-09-18 |
| EP4293024A1 (en) | 2023-12-20 |
| MX2023009521A (es) | 2023-08-24 |
| CR20230404A (es) | 2023-09-21 |
| PE20240235A1 (es) | 2024-02-16 |
| AR124870A1 (es) | 2023-05-17 |
| JPWO2022173032A1 (es) | 2022-08-18 |
| KR20230145361A (ko) | 2023-10-17 |
| US20240182483A1 (en) | 2024-06-06 |
| JP2022191505A (ja) | 2022-12-27 |
| DOP2023000161A (es) | 2023-09-29 |
| CN116848120A (zh) | 2023-10-03 |
| AU2022221145A1 (en) | 2023-09-21 |
| TW202245751A (zh) | 2022-12-01 |
| WO2022173032A1 (ja) | 2022-08-18 |
| CA3211051A1 (en) | 2022-08-18 |
| IL305077A (en) | 2023-10-01 |
| ECSP23067156A (es) | 2023-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023002383A1 (es) | Compuesto de quinazolina para inducir la degradación de la proteína kras mutante g12d | |
| CO2019008487A2 (es) | Compuesto de quinazolina | |
| CL2023000848A1 (es) | Terapia de combinación que incluye inhibidor de krasg12c y agente farmacéuticamente activo para tratar cáncer | |
| CO2018012894A2 (es) | Derivados de pirazol como inhibidores de calicreína plasmática | |
| ECSP19082194A (es) | Antimitoscinas: inhibidores específicos de la biogénesis mitocondrial para erradicar células madre cancerosas | |
| EA201690980A1 (ru) | Комбинированная терапия, включающая ингибитор mdm2 и один или более дополнительных фармацевтически активных агентов, для лечения различных видов рака | |
| EA201892510A2 (ru) | Комбинированная терапия для лечения рака | |
| ECSP18073366A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| CL2020002512A1 (es) | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak. | |
| BR112012021086A2 (pt) | composições farmacêuticas de composto espiro-oxindole para administração tópica e seu uso como agentes terapêuticos | |
| CO2019002246A2 (es) | Compuesto heterocíclico nitrogenado bicíclico | |
| CO2023001561A2 (es) | Combinaciones para el tratamiento de cáncer | |
| CL2023000524A1 (es) | Compuestos fosfolípidos y usos de los mismos | |
| SG11201908234WA (en) | Pharmaceutical composition comprising compound capable of penetrating blood-brain barrier as effective ingredient for preventing or treating brain cancer | |
| PE20151751A1 (es) | Metodos de tratamiento de la deficiencia de hierro con pirofosfato ferrico soluble | |
| CL2022000214A1 (es) | Inhibidores de enzimas | |
| CO2022000270A2 (es) | Inhibidores de enzimas | |
| CL2023002549A1 (es) | Ciertos compuestos de pladienolida y métodos de uso (divisional). | |
| ECSP20023626A (es) | Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3 | |
| CO2023008271A2 (es) | Compuesto de heteroarilcarboxamida | |
| BR112022009710A2 (pt) | Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2 | |
| BR112019022459A2 (pt) | Agente terapêutico para câncer no sangue | |
| BR112023006143A2 (pt) | Composição farmacêutica para prevenir ou tratar doença hepática colestática, contendo beta-lapachona como ingrediente ativo | |
| BR112019006633A2 (pt) | combinações farmacêuticas de inibidor de histona desacetilase e inibidor de proteassoma ou fármaco imunomodulador para o tratamento de câncer hematológico | |
| BR112019001808A2 (pt) | composição farmacêutica anticâncer |